Información del artÃculo
El Texto completo está disponible en PDF
Bibliografía
[1.]
I. Alonso, E. Regidor, C. Rodríguez, J.L. Gutiérrez-Fisac.
Principales causas de muerte en España, 1992.
Med Clin (Barc), 107 (1996), pp. 441-445
[2.]
R. Gisbert, M. Brosa, M. Figueras, E. Mindan, J. Rovira.
El coste de la enfermedad en España: el coste de las enfermedades cardiovasculares.
[3.]
K.M. Anderson, P.W.F. Wison, P.M. Odell, W.B. Kannel.
An updated coronary risk profile. A statement for health professionals.
Circulation, 83 (1991), pp. 356-362
[4.]
National Cholesterol Education Program Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
[5.]
ATP II Panel.
Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
JAMA, 269 (1993), pp. 3015-3023
[6.]
P. Plans-Rubió.
Cost-effectiveness analysis of treatments to reduce cholesterol levels, blood pressure and smoking for the prevention of coronary heart disease. Evaluative study carried out in Spain.
Pharmacoeconomics, 13 (1998), pp. 623-643
[7.]
K. Field, M. Thorogood, C. Silagy, C. Normand, C. O'Neill, J. Muir.
Strategies for reducing risk factors in primary care: which is most cost effective?.
BMJ, 310 (1995), pp. 1109-1112
[8.]
T. Van der Weijden, J.A. Knottnerus, A.J.H.A. Ament, H.E.J.H. Stoffers, R.P.T.M. Grol.
Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.
J Epidemiol Community Health, 52 (1998), pp. 586-594
[9.]
J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, et al.
Prevención primaria de los eventos coronarios agudos con lovastatina en varones y mujeres con concentraciones promedio de colesterol. Resultados del AFCAPS/ TexCAPS.
JAMA, 7 (1998), pp. 305-314
[10.]
J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A. Ross Lorimer, P.W. Macfarlane, et al.
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
N Engl J Med, 333 (1995), pp. 1301-1307
[11.]
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.
Prevention of cardiovascular events and death with pravastatin in patients with coronay heart disease and broad range of initial cholesterol levels.
N Engl J Med, 339 (1998), pp. 1349-1357
[12.]
Scandinavian Simvastatin Survival Study Group.
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study Group (4S).
Lancet, 344 (1994), pp. 1383-1389
[13.]
F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, et al.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.
N Engl J Med, 335 (1996), pp. 1001-1009
[14.]
Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M et al. A randomized placebo controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty: final results of the fluvastatin angiographic restenosis trial (FLARE). Eur Heart J (en prensa)
[15.]
S.A. Finkler.
The distinction between cost and charges.
Ann Intern Med, 96 (1982), pp. 102-109
[16.]
M.E. Spearman, K. Summers, V. Moore, R. Jacqmin, G. Smith, S. Groshen.
Cost-effectiveness of initial therapy with 3-hidroxy-3-methilglutaryl coenzyme A reductase inhibitors to treat hypercolesterolaemia in a primary care setting of a managed care organization.
Clin Ther, 19 (1997), pp. 582-602
[17.]
S.X. Kong, S.K. Gandhi, S.Y. Crawford, J.D. Seeger.
Pharmacoeconomic evaluation of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia.
Am J Man Care, 2 (1996), pp. 1055-1073
[18.]
C.B. Blum.
Comparison of properties of four inhibitors of 3-hydroxy-3-methilglutaryl coenzyme A reductase.
Am J Cardiol, 73 (1994), pp. 3-11
[19.]
L.L. Martens, R. Guibert.
Cost-effectiveness of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductse inhibitors in the primary prevention of coronary heart disease.
Clin Ther, 16 (1994), pp. 1052-1062
[20.]
S.X. Kong, S.Y. Crawford, S.K. Gandhi, J.D. Seeger, G.T. Schumock, N.P. Lam, et al.
Efficacy of HMG-CoA reductase inhibitors in the treatment of hypercholesterolemia: a meta-analysis of clinical trials.
Clin Ther, 19 (1997), pp. 778-797
[21.]
A.J. Jovell, M.D. Navarro-Rubio, M. Aymerich, M. Serra-Prat.
Metodología de diseño y elaboración de guías de práctica clínica en atención primaria.
Aten Primaria, 20 (1997), pp. 259-266
[22.]
M.F. Drummond, B. O'Brien, G.L. Stoddart, G.W. Torrance.
Methods for the economic evaluation of health care programmes.
2.a,
[23.]
G. Pérez, A. Pena, J. Sala, P. Roset, R. Masià, J. Marrugat.
and the REGICOR Investigators. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992.
Intern J Epidemiol, 27 (1998), pp. 599-604
[24.]
R. Masià, A. Pena, J. Marrugat, J. Sala, J. Vila, M. Pavesi, et al.
High prevalence of cardiovascular risk factors in Gerona, spain, a province with low myocardial infraction incidence.
J Epidemiol Community Health, 52 (1998), pp. 707-715
[25.]
M. Sentí, J. Masià, A. Pena, R. Elosua, C. Aubó, M. Bosch, et al.
Determinantes antropométricos de la concentración sérica del colesterol de las lipoproteínas de alta densidad en un estudio de base poblacional. El estudio REGICOR.
Rev Esp Cardiol, 51 (1998), pp. 979-987
[26.]
C. Brotons.
Implicaciones en la práctica clínica de los megaestudios sobre prevención primaria con estatinas.
Rev Esp Cardiol, 50 (1997), pp. 295-299
[27.]
A.J. Jovell, E. Jovell.
Evidencia científica y análisis económico: ¿dos conceptos excluyentes?.
Revista Española de Farmaeconomía, (1998), pp. 23-29
[28.]
N. Bradshaw, R. Walker.
Prescription of statins: cost implications of evidencebased treatment applied to a health authority population.
J Clin Pharm Ther, 22 (1997), pp. 379-389
[29.]
J. Rovira.
Standardizing economic appraisal of health technologies in the European Union.
Soc Sci Med, 38 (1994), pp. 1675-1678
[30.]
Report from the EUR-ASSESS project.
EUR-ASSESS project subgrup on dissemination and evaluation of impact.
Int J Technol Assess Health Care, 13 (1997), pp. 220-286
[31.]
Australia Commonwealth Department of Health, Housing and Community Services.
Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee.
[32.]
Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
Guidelines for economic evaluation of pharmaceuticals: Canada.
[33.]
Ontario Ministry of Health.
Ontario guidelines for economic analysis of pharmaceutical products.
[34.]
England and Wales Department of Health.
Guidelines on good practice in the conduct of economic evaluation of medicines.
[35.]
Cost-effectiveness in health care and medicine,
Copyright © 2000. Elsevier España, S.L.. Todos los derechos reservados
